3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Thoracic
2
Head & Neck
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
8
Fallopian Tube Neoplasms
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
4
Melanoma
3
Carcinoma, Hepatocellular
3
Stomach Neoplasms
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pelvic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Interventions
pembrolizumab
41
Nivolumab
13
Cyclophosphamide
10
Carboplatin
10
olaparib
7
Paclitaxel
7
Ipilimumab
7
fludarabine
6
Gemcitabine
6
durvalumab
5
lenvatinib
4
cemiplimab
4
atezolizumab
4
Specimen Handling
4
Oxaliplatin
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Fulvestrant
4
Fluorouracil
4
Bevacizumab
4
veliparib
3
spartalizumab
3
sacituzumab govitecan
3
liposomal doxorubicin
3
avelumab
3
aldesleukin
3
Taxes
3
Interleukin-2
3
Doxorubicin
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
X-Rays
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled